Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (EMBODY 1)

• The percent of subjects meeting treatment response criteria at Week 24 according to a combined response index [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  The percent of subjects meeting treatment response criteria at Week 24 according to a combined response index
• The percent of subjects meeting treatment response criteria at Week 12 according to a combined response index [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  The percent of subjects meeting treatment response criteria at Week 12 according to a combined response index
• The percent of subjects meeting treatment response criteria at Week 36 according to a combined response index [ Time Frame: Week 36 ] [ Designated as safety issue: No ]
  The percent of subjects meeting treatment response criteria at Week 36 according to a combined response index
• Change from Baseline in daily corticosteroid dose at week 24 [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]
  Change from Baseline in daily corticosteroid dose at week 24
• Change from Baseline in daily corticosteroid dose at week 48 [ Time Frame: Baseline, Week 48 ] [ Designated as safety issue: No ]
  Change from Baseline in daily corticosteroid dose at week 48

The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE)

• Drug: Epratuzumab
  600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
• Drug: Epratuzumab
  1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
• Drug: Placebo
  Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles

• Placebo Comparator: Placebo (Weekly infusion)
  Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
  Intervention: Drug: Placebo
• Experimental: Epratuzumab 600 mg per week
  600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
  Intervention: Drug: Epratuzumab
• Experimental: Epratuzumab 1200 mg every other week
  1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
  Interventions:

  • Drug: Epratuzumab
  • Drug: Placebo

Inclusion Criteria:

• Positive antinuclear antibodies (ANA) at Screening (Visit 1)
• Current clinical diagnosis of Systemic Lupus Erythematosus (SLE) by American College of Rheumatology (ACR) criteria such that at least 4 of the 11 criteria are met
• Active moderate to severe SLE activity as demonstrated by the British Isles Lupus Assessment Group Index (BILAG)
• Active moderate to severe SLE disease as demonstrated by SLEDAI total score.
• On stable SLE treatment regimen, including mandatory corticosteroids and immunosuppressants or antimalarials

Exclusion Criteria:

• Subjects who are breastfeeding, pregnant, or plan to become pregnant
• Subjects with active, severe SLE disease activity which involves the renal system
• Subjects with active, severe, neuropsychiatric SLE, defined as any neuropsychiatric element scoring BILAG level A disease.
• Subjects with the evidence of an immunosuppressive state
• Subjects who, in the opinion of the investigator, are at a particularly high risk of significant infection
• History of malignant cancer, except the following treated cancers: cervical carcinoma in situ, basal cell carcinoma, or dermatological squamous cell carcinoma.
• Subjects receiving any live vaccination within the 8 weeks prior to screening (Visit 1).
• Subjects with history of infections, including but not limited to concurrent acute or chronic viral hepatitis B or C
• Subjects with substance abuse or dependence or other relevant concurrent medical condition
• Subjects with history of thromboembolic events within 1 year of screening Visit.
• Subjects with significant hematologic abnormalities
• Subject has received treatment with other anti- B cell antibodies within 12 months prior to screening (visit 1)
• Subject use of oral anticoagulant (not including) nonsteroidal anti-inflammatory drugs (NSAIDs) within 12 weeks prior to screening (Visit 1)
• Subject has previously participated in this study or has previously received epratuzumab treatment.